VERTEX PHARMACEUTICALS INC / MA

The names, ages and positions held by our executive officers are as follows:

Dr. Kewalramani has been our Chief Executive Officer (CEO”) and President since April 2020 and a member of our

Board of Directors since February 2020. Dr. Kewalramani was our Executive Vice President and Chief Medical Officer from

April 2018 through April 2020. She was our Senior Vice President, Late Development from February 2017 until April 2018.

Dr. Kewalramani also served on the board of Ginkgo Bioworks from September 2021 to June 2024. From August 2004 to

January 2017, she served in roles of increasing responsibility at Amgen Inc., most recently as Vice President and Head of

U.S. Medical Organization. From 2014 through 2019, Dr. Kewalramani was the industry representative to the FDA’s

Endocrine and Metabolic Drug Advisory Committee. She completed her internship and residency in Internal Medicine at the

Massachusetts General Hospital and her fellowship in Nephrology at the Massachusetts General Hospital and Brigham and

Women’s Hospital combined program. Dr. Kewalramani holds a B.A. from Boston University and an M.D. from Boston

University School of Medicine. She is an alumna of the Harvard Business School, having completed the General

Management Program.

Dr. Leiden is our Executive Chairman, a position he has held since in April 2020. He was our Chief Executive Officer

and President from 2012 through March 2020. He has been a member of our Board of Directors since July 2009, the

Chairman of our Board of Directors since May 2012, and served as our lead independent director from October 2010 through

December 2011. Dr. Leiden was a Managing Director at Clarus Ventures, a life sciences venture capital firm, from 2006

through January 2012. Dr. Leiden was President and Chief Operating Officer of Abbott Laboratories, Pharmaceuticals

Products Group, and a member of the Board of Directors of Abbott Laboratories from 2001 to 2006. From 1987 to 2000, Dr.

Leiden held several academic appointments, including the Rawson Professor of Medicine and Pathology and Chief of

Cardiology and Director of the Cardiovascular Research Institute at the University of Chicago, the Elkan R. Blout Professor

of Biological Sciences at the Harvard School of Public Health, and Professor of Medicine at Harvard Medical School. He is

an elected member of both the American Academy of Arts and Sciences and the Institute of Medicine of the National

Academy of Sciences. Dr. Leiden was a director and the non-executive Vice Chairman of the board of Shire plc, from 2006

to January 2012, a director of Quest Diagnostics, from December 2014 to May 2019, and the Chairman of Revolution

Healthcare Acquisition Corp., from April 2021 to December 2022. Dr. Leiden received his M.D., Ph.D. and B.A. degrees

from the University of Chicago.

Dr. Atkinson has been our Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical

Sciences and Manufacturing Operations since August 2023. He previously served as our Senior Vice President, Head of

Commercial Manufacturing and Supply Chain since July 2020. Prior to joining us, Dr. Atkinson served in various roles at

Bristol-Myers Squibb Co., including as Senior Vice President, Global Manufacturing Operations from September 2019 to

June 2020; Vice President and Integration Leader, Corporate Cell Therapy and Global Development and Manufacturing from

January 2019 to September 2019; Vice President, Internal Manufacturing, Biologics from June 2017 to January 2019; and

Vice President, Biologics Development and Clinical Manufacturing from 2012 to June 2017. Before Bristol-Myers Squibb,

he held various roles at Cook Pharmica, LLC (now owned by Novo Holdings) and Eli Lilly. Dr. Atkinson served as a

member of the Board of Directors of 89bio, Inc. from February 2022 until October 2025, when it was acquired by Roche. Dr.

Atkinson holds a B.S. in Biology from Indiana University and a Ph.D. in Biological Sciences from Stanford University.

Mr. Biller has been our Executive Vice President, Chief Legal Officer since September 2022. From November 2019 until

he joined us, Mr. Biller served in several executive roles at Agios Pharmaceuticals, Inc., including Chief Legal Officer and,

most recently, Chief Financial Officer and Head of Corporate Affairs. Prior to Agios, he served as Executive Vice President,

General Counsel at Celgene from July 2018 to November 2019, where he was responsible for their global legal function, and

served as Senior Vice President, Tax and Treasury from 2011 to June 2018. Prior to Celgene, Mr. Biller was General

Counsel, Chief Tax Officer and Secretary at Bunge Limited, a global publicly traded agriculture and food company. Earlier in

his career he held various leadership roles at Alcon, Inc. and was a partner at Hopkins & Sutter and Foley & Lardner. Mr.

Biller holds a B.A. from Brown University and a J.D. from Yale Law School.

Dr. Bozic is our Executive Vice President, Global Medicines Development and Medical Affairs, a position she has held

since October 2019, and she has been our Chief Medical Officer since April 2020. She was our Senior Vice President and

Head of Global Clinical Development from May 2019 to October 2019. Prior to joining us, Dr. Bozic spent more than 20

years at Biogen Inc., a biotechnology company focused on neurological diseases, most recently as Senior Vice President of

Global Development and Portfolio Transformation from 2015 to May 2019 and as Senior Vice President of Clinical and

Safety Sciences from 2013 to 2015. Dr. Bozic has served as the industry representative to the FDA’s Risk Communication

Advisory Committee, and was a member of PhRMA’s Clinical and Preclinical Development Committee and the Board of

Managers at BioMotiv. She received her M.D., C.M., completed her residency, and was Chief Resident in Internal Medicine

at McGill University. She completed her fellowship in Pulmonary and Critical Care Medicine at Brigham and Women’s

Hospital and was an Associate Physician at Beth Israel Deaconess Medical Center and Harvard Medical School before

joining the biopharmaceutical industry.

Dr. Bunnage is our Executive Vice President and Chief Scientific Officer, a position he has held since February 2026. He

was our Senior Vice President & Head of Global Research from March 2024 through January 2026, our Senior Vice

President & Head of Research from July 2021 to March 2024, and our Senior Vice President & Site Head, Boston Research,

from August 2016 to July 2021. Prior to joining Vertex, Dr. Bunnage had a 20-year career at Pfizer Inc. where he held

positions of increasing responsibility, including Vice President, Worldwide Medicinal Chemistry and Head of Medicinal

Chemistry, Sandwich Laboratories. Dr. Bunnage is a Fellow of the Royal Society of Chemistry and a Fellow of the Royal

Society of Biology. He also serves as a visiting professor in chemistry at the University of Oxford, United Kingdom, and is a

member of the Strategic Advisory Board for the Department of Chemistry at the University of Durham, United Kingdom. Dr.

Bunnage received his B.Sc in Chemistry from the University of Durham and his D.Phil in Chemistry from the University of

Oxford. He completed his postdoctoral research as a NATO Fellow at The Scripps Research Institute in La Jolla, California.

Mr. McKechnie is our Executive Vice President, Chief Commercial Officer, a position he has held since July 1, 2025.

Mr. McKechnie previously served as our Senior Vice President, Head of North America Commercial from October 2018 to

July 2025, and as our Vice President of Global Marketing from June 2013 to September 2018. Prior to joining Vertex, Mr.

McKechnie held positions of increasing responsibility at Novartis AG, including Vice President, Respiratory Franchise from

January 2013 to June 2013; Vice President and Head Brand Maximization and Established Medicines from April 2012 to

April 2013; and Vice President, Cardiovascular Marketing from November 2008 to March 2012. Before Novartis, Mr.

McKechnie held various roles at GlaxoSmithKline plc. Mr. McKechnie holds a Business & Marketing degree from the

University of Plymouth in England.

Mr. Sachdev is our Executive Vice President, Chief Patient and External Affairs Officer, a role he has held since July

2023. From October 2019 to July 2023, he was our Executive Vice President, Chief Patient Officer. In addition, Mr. Sachdev

served in the role of Chief of Staff to the CEO from April 2020 to March 2023. He served as our Executive Vice President

and Chief Regulatory Officer from January 2017 until September 2019, and as our Executive Vice President, Policy, Access

and Value from October 2014 through December 2016. In 2010, he established our first international commercial operations

in Canada. In 2007, he joined us as a Senior Vice President, to establish our government affairs and public policy activities,

as well as our patient advocacy programs. Prior to joining us, Mr. Sachdev served as Executive Vice President, Health, of the

Biotechnology Industry Organization (BIO) and was the Deputy Commissioner for Policy at the FDA, where he also served

in several other senior positions. Prior to the FDA, Mr. Sachdev served as Majority Counsel to the Committee on Energy and

Commerce in the U.S. House of Representatives and practiced law at the American Chemistry Council, and subsequently at

the law firm of Ropes & Gray LLP. He served as a member of the Board of Directors of Eiger BioPharmaceuticals from

April 2019 to September 2024. Mr. Sachdev holds a B.S from Carnegie Mellon University and a J.D. from Emory University

School of Law.

Dr. Tatsis is our Executive Vice President, Chief Regulatory and Quality Officer, a position she has held since August

2020. Previously, she was our Senior Vice President and Chief Regulatory Officer from October 2019 to August 2020, and

our Senior Vice President, Global Regulatory Affairs from September 2017 to October 2019. Prior to joining us, Dr. Tatsis

held positions of increasing responsibility at several pharmaceutical companies, including Sanofi, Stemnion, Pfizer, and

Wyeth. Most recently, from 2014 to 2017, she was Vice President, Head of Global Regulatory Affairs, at the Sanofi

Genzyme Business Unit focused on Inflammation/Immunology, Rare Disease, Multiple Sclerosis, Ophthalmology,

Neurology, and Oncology/Immuno-Oncology. Dr. Tatsis also worked as an associate staff scientist and research fellow in

Immunology and Vaccine Development at the Wistar Institute and completed a post-doctoral research fellowship in

Immunology at Thomas Jefferson University. Dr. Tatsis has served as a member of the board of directors at Odyssey

Therapeutics since October 2025, and previously served on the board of directors of Verve Therapeutics from June 2024 until

July 2025, when it was acquired by Eli Lilly. She received her Ph.D. in Cell and Molecular Biology from the University of

Vermont and holds a B.S. in Biology from Temple University.

Mr. Wagner is our Executive Vice President, Chief Operating & Financial Officer, a position he has held since July

2025. Mr. Wagner was our Executive Vice President, Chief Financial Officer from April 2019 through June 2025. Prior to his

role at Vertex, Mr. Wagner was Chief Financial Officer and Executive Vice President, Finance, of Ortho Clinical

Diagnostics, a Carlyle Group portfolio company, from June 2015 to March 2019. In that role, he led the finance, accounting,

tax, treasury, global financial systems, lender relations, and acquisitions and divestiture groups. From July 2012 to June 2015,

Mr. Wagner served as Executive Vice President, Chief Financial Officer of Bruker Corporation, a scientific instruments

manufacturer. Prior to that, Mr. Wagner served as Chief Financial Officer for Progress Software Corporation, a provider of

enterprise software, and Millipore Corporation, a global provider of products and services in the life science tools market. Mr.

Wagner served as a director of Good Start Genetics, Inc., from April 2014 to August 2017 and served as a director and

member of the Audit Committee of Bruker Corporation from August 2010 to June 2012. He has served as a member of the

Board of Directors of The TJX Companies, Inc., since September 2023. Mr. Wagner holds a B.S. in Accounting from Boston

College and a M.B.A from Harvard Business School.

Ms. Ambrose is our Senior Vice President, Chief Accounting Officer, a position she has held since May 2021. Ms.

Ambrose previously served as our Senior Vice President, Accounting, Tax, Treasury, Strategic Sourcing and Corporate

Services since March 2021. From February 2003 until she joined us, Ms. Ambrose held roles of increasing responsibility at

Boston Scientific Corporation, a medical device company, most recently as Vice President of Finance and Controller of the

Global Endoscopy Division from July 2019 to March 2021 and as Vice President of Global Internal Audit from February

2017 to June 2019. Prior to Boston Scientific Corporation, Ms. Ambrose served as an accountant at Ernst & Young LLP. She

received her B.S. in Commerce from the University of Virginia and is a Certified Public Accountant.